The Inovoject device launched by Embrex has marked its 30th anniversary. When it was launched the device enabled the poultry industry to improve health by tackling Marek’s Disease before it reached flocks.
Since then, the technology has continued to develop and expand to cover other common poultry diseases.
“Embrex BioDevices are now used to inject more than 20 billion eggs every year in 30 countries around the world. And we are incredibly proud of the positive impact it has had since it was first used commercially,” said Glenn David of Embrex. “It has grown from a completely new technology into an industry standard which has played a major part in improving the health, welfare, profitability and sustainability of modern poultry production.”